Blue Flower

Usage of Cookies
We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy. Imprint

Dear Madam, Dear Sir

On behalf of the entire NOXXON team, I am pleased to welcome you to this section of our website. NOXXON is a European biopharmaceutical company developing anticancer treatments targeting the tumor microenvironment quoted on Euronext Growth in Paris, formerly Alternext.

Our goal is to significantly improve cancer therapies, including immuno-oncology approaches, such as checkpoint inhibitors, and standard therapies such as chemo- and radio-therapy.

2018 was an eventful year for NOXXON, with the publication of the results of the combination trial of NOX-A12 + immunotherapy in colorectal and pancreatic cancers in which was conducted in collaboration with Merck & Co/MSD to assess the safety and activity of NOX-A12 in patients with advanced cancer. We also prepared the launch of a combination trial of NOX-A12 + radiotherapy in brain cancer and continued preclinical work with NOX-E36 to extend its action in oncology.

In order to finance our clinical developments in oncology, we have launched a €3.9 million capital increase with preferential rights, which allows NOXXON shareholders to subscribe, until July 17, 2019, for new shares at a unit price of €0.65 and thus benefit from a 15.7% discount on the share closing price on June 24, 2019.

The majority of proceeds the capital increase would be allocated to advancing the clinical product portfolio of NOXXON, and to finance:

-    the initiation of the NOX-A12 and radiotherapy trial in brain cancer,
-    the completion of patient follow-up from the pancreatic and colorectal cancer trial,
-    further preclinical work on the NOX-E36 molecule
-    the Company's other operating expenses, including general and administrative costs.

You will find all the information needed to participate in this rights offering in the press release published on June 26, 2019.

Best regards

Aram Mangasarian, PhD
Chief Executive Officer

• Download the initiation report on NOXXON by Aurgalys
➥ See latest update note from Aurgalys here
• Download the re-initiation report (Dec 2018) on NOXXON by Invest Securities


L’entretien avec Aram Mangasarian, PDG de Noxxon, dans Le journal des biotechs de Boursorama pour brosser les perspectives de la société et de ses deux produits NOX-A12 et NOX-E36.
Le PDG de NOXXON Pharma annonce le transfert de l’action vers le compartiment EURONEXT GROWTH pour être cotée en continu.
NOXXON CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications on BIO-Europe Spring 2017